Neurophet, a brain imaging AI solution company, said Thursday that it has signed an agreement with AriBio, a developer of treatments for neurodegenerative disorders, to co-study in the global phase 3 clinical trial of AR1001, an oral Alzheimer's disease treatment.

Under the accord, Neurophet will provide its brain imaging analytics technology to AriBio's AR1001 global phase 3 clinical trial. In addition, the companies will collaborate on joint research and business development using data accumulated from the trial.

Neurophet has developed Neurophet Scale PET, which quantifies the deposition of amyloid beta protein, the causative agent of Alzheimer's disease, in specific areas of the brain, and Neurophet Aqua, which analyzes white matter degeneration, found in MRI of the brain of Alzheimer's disease patients.

The process of enrolling patients in clinical trials typically requires a nuclear medicine specialist to read brain images, which can be difficult or time-consuming.

However, Neurophet can provide objective data by analyzing brain images, enabling medical staff to make clearer judgments and help scientifically analyze the correlation between brain conditions and drug effects, using various data such as the degree of amyloid accumulation, brain atrophy, and white matter degeneration.

The global phase 3 clinical trial of AR1001, also known as Polaris-AD, was approved by the FDA in December 2022 and started patient dosing with the plan for AriBio to conduct the studies in Korea, China, and Europe.

"We are pleased to have Neurophet participate in the global clinical trial of AR1001 through this agreement and will utilize Neurophet's AI technology to secure high-quality clinical results," said Choung Jai-jun, CEO of AriBio. "Our goal is to complete the global clinical trial in multiple countries simultaneously to provide treatment opportunities for more patients in the global dementia treatment market."

"As dementia remains an incurable disease, entering a global phase 3 clinical trial for a dementia treatment is of great significance," said Neurophet CEO Been Jun-kil. "The use of Neurophet's brain image analysis technology in the AR1001 phase 3 trial will facilitate a smoother and faster clinical trial process and enable us to scientifically analyze the effectiveness of future therapeutic agents to reduce clinical study costs and improve clinical study results"